High-Dose Methotrexate Seems to Benefit Only to Standard-Risk BCP-ALL Patients with Good Early Response to Chemotherapy: Final Analysis of the FRALLE93B Study

Leblanc, Thierry;Vermylen, Christiane;Landman-Parker, Judith;Auclerc, Marie-Francoise;Baruchel, Andre;et.al.
(2008) 50th Annual Meeting of the American- Society-of-Hematology — Location: San Francisco (Ca) (6.December.2008)

Files

No attached file found for this publication.

Details

Authors
  • Leblanc, Thierry
    Author
  • Vermylen, ChristianeUCLouvain
    Author
  • Landman-Parker, Judith
    Author
  • Auclerc, Marie-Francoise
    Author
  • Baruchel, Andre
    Author
Show more
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Leblanc, T., Vermylen, C., Landman-Parker, J., Auclerc, M.-F., Desseaux, K., Schmitt, C., Gandemer, V., Lejars, O., Vannier, J.-P., Demeocq, F., Berthou, C., Couillault, G., Pautard, B., Berger, C., De Lumley, L., Debre, M., Michel, G., Perel, Y., Leverger, G., & Baruchel, A. (2008). High-Dose Methotrexate Seems to Benefit Only to Standard-Risk BCP-ALL Patients with Good Early Response to Chemotherapy: Final Analysis of the FRALLE93B Study. Blood, 112(11), 10. https://hdl.handle.net/2078.5/147211 (Original work published 2008)